Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 2272

Reviews
Year : 2018 | Month : August | Volume : 12 | Issue : 8 | Page : XE01 - XE06

A Review on Newer Tyrosine Kinase Inhibitors and their Uses

Nithu M Kumar, Meenu Mathew, KN Anila, S Priyanka

1. Pharm D Intern, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. 2. Pharm D Intern, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. 3. Lecturer, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India. 4. Pharm D Intern, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.

Correspondence Address :
Ms. KN Anila,
Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi-682041, Kerala, India.
E-mail: anilakn@aims.amrita.edu

Abstract

Tyrosine Kinase Inhibitors (TKI) can reversibly or irreversibly block the signaling pathway occurring in the extracellular part of the receptor by inhibiting Tyrosine Kinase (TK) phosphorylation. This review included the drugs that were newly marketed or drugs with newer approved uses after 2015, such as Gefitinib, Osimertinib, Crizotinib, Alectinib, Ibrutinib, Cabozantinib. Brigatinib and Lorlatinib are investigational drugs that have not been approved and have shown promising results in trials for the treatment of Anaplastic Lymphoma Kinase (ALK) positive metastatic Non Small Cell Lung Carcinoma (NSCLC). Gefitinib, Osimertinib, Crizotinib, Alectinib were approved for treating NSCLC. Cabozantinib and Lenvatinib were approved for treating renal cell carcinoma and thyroid carcinoma. Ibrutinib was approved for treatment of Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Waldenström macroglobulinemia, previously treated Mantle cell lymphoma and relapsed or refractory Marginal zone lymphoma. TKI have promising efficacy in treating a wide range of oncologic diseases. Hand-foot-skin reaction are the most common side effect of drugs in this category, however, TKI are found to have relatively fewer side effects compared to other anti cancer drugs.

Keywords

Anaplastic lymphoma kinase, Bruton's tyrosine kinase inhibitor, Epidermal growth factor receptor inhibitor, Non small cell lung carcinoma, Vascular endothelial growth factor

How to cite this article :

Nithu M Kumar, Meenu Mathew, KN Anila, S Priyanka. A REVIEW ON NEWER TYROSINE KINASE INHIBITORS AND THEIR USES. Journal of Clinical and Diagnostic Research [serial online] 2018 August [cited: 2018 Aug 14 ]; 12:XE01-XE06. Available from
http://www.jcdr.net/back_issues.asp?issn=0973-709x&year=2018&month=August&volume=12&issue=8&page=XE01-XE06&id=11957

DOI and Others

DOI: 10.7860/JCDR/2018/31031.11957

Date of Submission: Jun 20, 2017
Date of Peer Review: Sep 12, 2017
Date of Acceptance: Jan 31, 2018
Date of Publishing: Aug 01, 2018

FINANCIAL OR OTHER COMPETING INTERESTS: NONE.

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2016: 132.37
  • SCOPUS
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhost
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com